Brain scan, cerebrospinal fluid analysis may help predict Alzheimers disease
A combination of brain scanning with a new imaging agent and cerebrospinal fluid (CSF) analysis has left neuroscientists encouraged that they may finally be moving toward techniques for diagnosing Alzheimers disease before its clinical symptoms become apparent. "When clinical symptoms start, the disease process has already been at work in the patient for many years and possibly even decades," explains Anne Fagan Niven, Ph.D., research associate professor of neurology at Washington University School of Medicine in St. Louis. "Up to 30 percent of neurons in vulnerable areas are already dead, and you cant get them back. So finding markers that can help us identify patients prior to symptoms is really our big push now."
With colleagues Mark Mintun, M.D., professor of radiology, and David Holtzman, M.D., the Andrew B. and Gretchen P. Jones Professor and head of the Department of Neurology, Fagan studied a group of 24 people that included individuals diagnosed with very mild and mild Alzheimers disease, and cognitively normal subjects. As expected, in patients with cognitive impairments, believed to be attributable to Alzheimers disease, researchers found low CSF levels of amyloid beta 42 (A-beta 42), the principal ingredient of the brain plaques that are characteristic of Alzheimers disease. In the same individuals, brain scans with a new imaging agent that reveals the presence of amyloid plaques in the brain were positive. What scientists didnt anticipate was that three cognitively normal subjects would have both low CSF levels of A-beta 42 and positive results from the brain scans. Fagan stressed that although this aspect of their findings was very intriguing, it doesnt prove that the three normal subjects will one day develop clinical Alzheimers disease.
"For now, definitive diagnosis of Alzheimers disease still cannot be made until autopsy," she says. "Its going to take a number of years for us to fully assess these results, because all we can do now is follow the participants closely to see if they eventually develop Alzheimers dementia." Fagan presents the results of the study at 10:15 a.m. on Nov. 15 at this years annual meeting of the Society for Neuroscience in Washington, D.C. The study will also appear in an upcoming issue of Annals of Neurology. Many prior studies have found that A-beta 42 levels drop in the cerebrospinal fluid of Alzheimers disease patients. A-beta 42 is naturally produced in the brain, and researchers suspect that the creation of amyloid plaques may be linked to breakdowns of the processes that degrade or normally clear A-beta 42 from the brain via the CSF and the bloodstream.
However, natural variations occur in CSF A-beta 42 levels in healthy subjects, and the amount this level drops in Alzheimers patients also varies. And that left no distinct level scientists could identify as a diagnostic marker characteristic of Alzheimers disease. Fagan wanted to see if useful distinctions could be made by combining data on CSF A-beta 42 levels with results from brain scans with a new imaging agent, PIB (for Pittsburgh compound B). Developed by researchers at the University of Pittsburgh, PIB temporarily sticks to amyloid plaques in the brain but washes clean in 30 to 60 minutes. Scientists can detect this sticking with a PET scanner. Using PIB data available from ongoing studies of research volunteers at the Memory and Aging Project at the Alzheimers Disease Research Center at Washington University, Fagan compared PIB scan results and levels of CSF A-beta 42.
"When I realized that everyone who was PIB positive also had lower CSF A-beta 42 levels, I had one of those aha! moments that makes it so exciting to be a scientist," Fagan says. Other CSF factors, such as levels of another form of A-beta and of a molecule found in the brain cell tangles created by Alzheimers disease, did not correlate with positive PIB scan results. "The hope is that 10-20 years from now, well give people a PIB scan, draw and analyze their CSF, and combine that with other factors to get a global score for their personal risk of Alzheimers disease," Fagan says. "We have disease-modifying treatments on the way to clinical trials right now, and tests that can help us detect Alzheimers earlier will both help us put those treatments to better use and assess the results they produce in patients."
Michael C. Purdy | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Scientists have developed a new method of characterizing graphene’s properties without applying disruptive electrical contacts, allowing them to investigate both the resistance and quantum capacitance of graphene and other two-dimensional materials. Researchers from the Swiss Nanoscience Institute and the University of Basel’s Department of Physics reported their findings in the journal Physical Review Applied.
Graphene consists of a single layer of carbon atoms. It is transparent, harder than diamond and stronger than steel, yet flexible, and a significantly better...
The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.
The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...